Premium
Autocrine motility factor and the extracellular matrix. II. Degradation or remodeling of substratum components directs the motile response of tumor cells
Author(s) -
Silletti Steve,
Paku Sandor,
Raz Avraham
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980330)76:1<129::aid-ijc20>3.0.co;2-6
Subject(s) - autocrine signalling , motility , extracellular matrix , fibronectin , microbiology and biotechnology , laminin , biology , growth factor , cancer research , receptor , immunology , biochemistry
Autocrine motility factor is a tumor‐secreted cytokine which regulates cellular growth and motility by a receptor‐mediated pathway. In the accompanying report (Part I of II), it was demonstrated that high (K1735‐M1) and low (K1735‐C1.11) metastatic murine melanoma cells display distinct adhesion and spreading characteristics which correlate with their differential spontaneous and stimulated migrations on the extracellular matrix components fibronectin, laminin and collagen IV. These parameters were further related to discrete profiles of focal adhesion plaque integrity and re‐organization. Here we describe unique migration patterns observed in these murine melanoma cells which reflect differences in degradation and/or remodeling of the cellular substratum. These profiles of matrix interaction were influenced distinctly by autocrine motility factor and dictated by both substrate composition and cellular phenotype. Since activation of the autocrine motility factor receptor stimulates invasion of a reconstituted basement membrane and enhances experimental metastasis by high‐ but not low‐metastatic K1735 cells, differences in the invasive phenotypes of these cells may be due in part to their differential responses to external stimuli coupled with internal propensities toward either matrix degradation and migration (high‐metastatic cells) or matrix remodeling and stasis (low‐metastatic cells). Int. J. Cancer 76:129–135, 1998.© 1998 Wiley‐Liss, Inc.